North America Polymyositis Market Size & Outlook, 2026-2034


North America Polymyositis Market Insights

  • As highlighted in Reed Intelligence analysis, the North America Polymyositis Market, valued at USD 396.29 Million in 2025, is estimated to achieve USD 727.42 Million by 2034.
  • The market is estimated to grow at a CAGR of 6.96% spanning 2026 to 2034.
  • By market size, Corticosteroids led the Treatment Type category in 2025.
  • The Treatment Type segment led by Biologics is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.

Other Key Findings


  • The global Polymyositis Market size saw North America holding a share of 30.96% in 2025.
  • United States is forecasted to account for the leading share of the global market by 2034.
  • In North America, Canada is forecasted to be the fastest-expanding market, projected to reach USD 197.17 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 396.29 Million
Market Size In 2034 USD 727.42 Million
Largest segment Corticosteroids
Units Revenue in USD Million
CAGR 6.96% (2026-2034)
Segmnetation Covered
North America
  1. United States
  2. Canada
Treatment Type
  1. Corticosteroids
  2. Immunosuppressants
  3. Biologics
  4. Others
Diagnosis Method
  1. Blood Tests
  2. Imaging Techniques
  3. Muscle Biopsy
  4. Electromyography
End-Use
  1. Hospitals
  2. Specialty Clinics
  3. Research Institutes
  4. Others
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends